New cancer drug combo enters first human safety tests
NCT ID NCT07362264
Summary
This is an early-stage study to check the safety and find the right dose of a new drug called SH006 injection when given with standard cancer medications. It will involve about 50 adults with advanced solid tumors, like liver cancer, that have not responded to at least one prior treatment. The main goal is to see how well patients tolerate the combination and to identify any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.